Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Withdrawn 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 2Thoracic 1Gynecologic 1Genitourinary 1Gastrointestinal 1

Conditions

Uterine Cervical Neoplasms 5Prostatic Neoplasms 3Colorectal Neoplasms 3Pancreatic Neoplasms 2Ovarian Neoplasms 2Neoplasms 2Melanoma 2Hemangiosarcoma 2Carcinoma, Non-Small-Cell Lung 2Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Sarcoma 1Refractory Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC) 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Neoplasm Metastasis 1Fibrolamellar hepatocellular carcinoma 1Endometrial Neoplasms 1Diabetes Mellitus, Insulin-Dependent, 12 1Carcinoma, Hepatocellular 1Advanced Solid Tumor 1

Interventions

spartalizumab 2pazopanib 2carotuximab 2belinostat 2balstilimab 2Ipilimumab 2Doxorubicin 2soblidotin 1TTI-621 1Injections 1Imatinib Mesylate 1Ifosfamide 1Fluorouracil 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Hemangiosarcoma × balstilimab × Clear all
NCT03860272 2026-03-30

Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer

Agenus Inc.

Phase 1 Active not recruiting
499 enrolled
GastrointestinalGenitourinaryGynecologicSarcomaThoracic

Fibrolamellar hepatocellular carcinoma, Carcinoma, Non-Small-Cell Lung, Hemangiosarcoma, Ovarian Neoplasms, Prostatic Neoplasms, Endometrial Neoplasms

NCT04607200 2022-01-11

AGEN2034 & AGEN1884 in Patients With Recurrent, Inoperable Angiosarcoma

Agenus Inc.

Phase 2 Withdrawn
Sarcoma

Hemangiosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡